Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial

Aims Evaluate anti‐interleukin‐1β ( IL ‐1β) antibody, canakinumab, in patients with type 2 diabetes and impaired glucose tolerance ( IGT ) in whom hyperglycaemia may trigger IL ‐1β‐associated inflammation leading to suppressed insulin secretion and β‐cell dysfunction. Methods This 4‐week, parallel‐group study randomized 190 patients with type 2 diabetes 2 : 1, canakinumab versus placebo, into the following treatment arms: metformin monotherapy,...